Yang Ce, Ji Xingyue, Vaskuri G S Sainaga Jyothi, Yang Xiaoxiao, Lu Wen, Yuan Zhengnan, Liu Dongning, Wang Siming, Tan Chalet, Wang Binghe
Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303 USA.
Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163 USA.
Med Chem Res. 2024 Nov;33(11):2122-2130. doi: 10.1007/s00044-024-03312-1. Epub 2024 Oct 24.
We have had a long-standing interest in developing organic prodrugs for controlled delivery of CO for various therapeutic applications. Based on an earlier approach of taking advantage of a cheletropic extrusion reaction of norbornadienone to release CO, a new structural scaffold of CO prodrugs has been designed using an adamantane moiety instead of aryl groups for stabilizing a critical precursor structure, cyclopentadienone. This approach allows for elimination of multiple aromatic groups on the previous scaffolds and offers a handle for installing additional moieties for improving solubility. Specifically, prodrugs with different solubilizing groups have been synthesized and assessed for their water solubility and potency in inhibiting inflammation using TNF-α as a marker. In cell-culture studies, varying potency was observed in a fashion consistent with the polarity of a prodrug being a key factoring affecting membrane permeability and thus the local concentration of CO intracellularly. However, these prodrugs all offer systemic availability of CO in animal models even if the prodrug does not appear to have the ability to traverse cellular membrane. Such results suggest that member permeability is not a major factor in determining the ability to deliver CO systemically. Further, caution is needed in directly extrapolating results from cell culture to animal models, especially for such a gaseous active principal.
长期以来,我们一直致力于开发有机前药,用于将一氧化碳(CO)可控地递送至各种治疗应用中。基于利用降冰片二烯酮的螯合环化加成反应释放CO的早期方法,我们设计了一种新的CO前药结构支架,使用金刚烷部分而非芳基来稳定关键前体结构环戊二烯酮。这种方法能够去除先前支架上的多个芳香基团,并为安装其他基团以改善溶解性提供了途径。具体而言,我们合成了具有不同增溶基团的前药,并以肿瘤坏死因子-α(TNF-α)为标志物评估了它们的水溶性和抑制炎症的效力。在细胞培养研究中,观察到不同的效力,其方式与前药的极性一致,而前药的极性是影响膜通透性进而影响细胞内CO局部浓度的关键因素。然而,即使前药似乎没有穿越细胞膜的能力,这些前药在动物模型中均能实现CO的全身可用性。这些结果表明,膜通透性不是决定CO全身递送能力的主要因素。此外,将细胞培养结果直接外推至动物模型时需要谨慎,尤其是对于这种气态活性成分。